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Abstract— The current gold standard diagnostic test for Johne’s 
disease (JD) is detecting Mycobacterium avium subsp. 
paratuberculosis (MAP) from fecal samples via culture and/or 
PCR.  Other commercially available JD diagnostic tests focus on 
the detection of specific antibodies within the serum or milk of 
infected ruminants. These tests have a high specificity but low 
their sensitivity and usually fail to diagnose the disease until later 
stages of the disease. The ideal diagnostic test should detect 
infected animals already during the silent phase. Here, we 
evaluate the use of new and established approaches to define the 
silent phase of JD in experimentally infected goats. None of the 
established diagnostic tests or new approaches for the detection 
of humoral and cellular immune responses were positive during 
the first year of infection. Only the characterization of various 
subsets of peripheral blood leukocytes and the weight 
development gave some indication for the presence of a chronic, 
but silent, infection. Weight differences were present throughout 
the first year. In addition, some of the subsets of leukocytes 
(WC1+  T cells, MHC class II+ leukocytes, CD1+ leukocytes, 
CD14+ granulocytes, and CD14+/MHC class II+ granulocytes) 
demonstrated significant differences, but only at certain time 
points. 
Keywords-Mycobacterium avium subsp. paratuberculosis; 
Johne’s disease; silent phase; diagnostics 
I.  INTRODUCTION 
Johne’s disease is a chronic intestinal disease in ruminants 
caused by Mycobacterium avium subspecies paratuberculosis 
(MAP) [1,2]. JD is commonly found in US dairy farms and at 
least one cattle with a positive MAP culture was detected in 
approximately 68 % of U.S. dairy cattle herds and in 95% of 
large herd with more than 500 dairy cows [3].  It shares with 
other mycobacterial diseases its chronic appearance 
[4,5,6,7,8,9].  While disease in wild ruminants is possible [10], 
JD is more often observed in domestic cattle, sheep, and goats.  
Most of these chronic mycobacterial infectious diseases have a 
late onset and Johne’s disease is no exception [11] with an 
average of two years but up to five years [12]. Animals 
usually acquire MAP early in life, in utero or from 
consumption of contaminated milk, feces, or water supplies. 
The progression of MAP infection, of which the last two are 
the actual Johne’s disease, is divided into four different 
distinct stages: silent, subclinical, clinical, advanced clinical 
[13]. In the silent stage there are no clinical or laboratory 
diagnostic indications of the infection. All diagnostic tests 
used so far are negative including culturing the pathogen from 
fecal samples. During the subclinical stage fecal shedding of 
the pathogen may be detected; this shedding is usually 
temporary and sporadic. Diagnostics tests are seldom 
indicative for the disease at this stage, and fecal culturing 
might be the only indication for JD. During the next two 
stages, clinical stage and advanced clinical stage, diagnostic 
tests are more often positive and animals show symptoms and 
signs for JD with weight loss and chronic diarrhea as the key 
characteristics. Even during these stages serological 
diagnostics are not always positive. Clinical symptoms during 
the later stages include a drastic decline in milk production 
and malabsorption of nutrients and osmotic diarrhea due to 
severe intestinal inflammation especially in dairy cattle, while 
in goats the clinical stages are dominated by anemia, 
emaciation and occasionally by diarrhea [14].  Most clinical 
animals shed large amounts of MAP in their feces and milk, 
spreading the disease to other members of the herd; however, 
some animals do not shed the bacteria at all.  Death from 
malnourishment ensues. 
 
The only effective control measure currently applied by most 
dairy farmers in the US is culling infected animals and/or 
instituting good herd management practices. While there are 
strong efforts to develop excellent vaccines [15,16], no 
successful efforts have been seen on the development of new 
diagnostic approaches to help in identify infected animals 
during the first two stages. 
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Economically, JD severely impacts dairy farmers [15,16].  
Infected cows in the clinical stages do not produce as much 
milk as their uninfected counterparts or cows without clinical 
symptoms.  Fecal shedding of MAP often occurs at or before 
the onset of clinical symptoms.  Once an infected animal is 
symptomatic, it has most likely spread the bacteria to other 
animals in the herd.  Diagnostic tests do exist for JD; however, 
while they do correctly diagnose animals at a frequency that 
allows for maintenance/decreased incidence of JD they only 
identify a portion of infected or diseased animals.  The ‘gold 
standard’ diagnostic method for JD was culturing MAP from 
fecal samples, while currently the detection of the pathogen by 
PCR from fecal samples is replacing fecal culturing.  While a 
positive result does indicate infection with nearly 100% 
certainty, fecal culturing only diagnoses animals that are 
already shedding MAP and consequently already infecting 
other animals.  Furthermore, one has to consider the 
possibility of passive shedding [17]. Ideally, a diagnostic test 
for JD would positively identify MAP infected animals before 
they shed bacteria. 
 
Eckstein et al (2006) recently discovered a MAP cell wall 
lipid not present in Mycobacterium avium subspecies avium, a 
bacterium that is physiologically similar to MAP and is 
common in the environment [18].  This lipid, termed Para-LP-
01, reacts via ELISA to serum from JD-positive cows but not 
JD negative cows, indicating that it may be useful as a 
diagnostic tool.  Since Para-LP-01 is, to the extent of our 
knowledge, unique to MAP, using it in diagnostic assays, such 
as the aforementioned ELISA, should significantly reduce the 
number of false positive results. 
 
Cytokine levels could be measured to monitor cell-mediated 
immune responses to MAP.  In experimentally infected cows 
and goats, elevated interferon-gamma (IFN), a TH1 
stimulatory cytokine, in response to Johnin purified protein 
derivative (JPPD) occurred before fecal shedding [19].  
Bovine macrophages infected with MAP secrete higher levels 
of Interleukin-10 (IL-10) than their uninfected counterparts 
[20].  Increased levels of IL-10 promote a TH2 response as 
opposed to a TH1 response, resulting in antibody production 
and decreased intracellular MAP killing.  Monitoring IFN 
and IL-10 levels in infected animals could help determine 
when the TH1 to TH2 shift occurs and whether cytokine 
production would be a valid diagnostic tool [21].  
 
All ruminants can develop JD, however, while the key animals 
of interest in the USA are dairy cattle because of the enormous 
losses associated with the disease [15,16], goats and sheep are 
the main focus in other countries.  There are two key questions 
associated with the first two stages: Why is there a late onset 
of the clinical characteristics, and what could be done to 
improve detection of infected animals. Long-term studies with 
experimentally infected animals might provide more insights 
into the immune responses during the early stages. In addition, 
following peripheral blood leukocyte population changes 
might provide indication on what might happen at the local 
level in the intestine.  In this study, we evaluated the use of 
various established and new disease-specific and none specific 
diagnostic approaches. 
 
II. MATERIALS AND METHODS 
A. Animals 
All research and housing procedures for the goats in this 
study were approved by Colorado State University IACUC and 
the approval number is #11-3120A. Twenty dairy goat kids of 
various breeds aged 3-5 days were purchased from CCI/Juniper 
Valley Products (Canon City, Colorado), a JD free goat dairy.  
The goat kids were housed on the Colorado State University 
Foothills Campus (Fort Collins, CO) in accordance with CSU 
animal ethics regulation.  The goat kids were individually fed 
pasteurized cow milk three times daily for the first two months. 
Each goat kid had its own feeding bottle and nipple. All goat 
kids were housed in the same barn prior inoculation at week 7. 
The barn was clean and disinfected before used.  Prior to 
weaning alfalfa hay was introduced to supplement the goats’ 
nutrition needs. Goats within the inoculated and non-inoculated 
groups were separated into different locations prior inoculation 
with MAP. Each group of goat kids was housed in non-
adjacent corrals with open barns (fully covered, front wall 
open, all other walls closed) at the CSU Foothills Campus. 
Both groups had access to at least 4000 m2 pasture. All corrals 
at CSU Foothills Campus are not attached to other corrals and 
have significant space in between the corrals. Water and salt 
stones were provided ad libitum. Goats were fully milk fed for 
7 weeks. Whole pasteurized cow milk was purchased from a 
local Walmart store (Walmart, Inc. Fort Collins, CO) in 1-
gallon containers. Goats were fed with warm milk, individually 
by hand. Milk feeding was reduced to twice a day for 6 weeks 
and than reduced to once a day for additional 6 weeks. During 
this time alfalfa hay was supplemented. After 12 weeks post 
infection all goats received alfalfa hay as food supply. At week 
6 post infection one goat died due to enterotoxaemia. 
B. Goat infection and preparation of the inoculum 
Goats were inoculated with MAP strain K-10 as described 
recently [22]. This strain is a bovine isolate from Nebraska and 
was provided to us by Dr. Vivek Kapur (University of 
Minnesota). The pathogen was grown on Middlebrook 7H11 
supplemented with 10% OADC (oleic acid, albumin, dextrose, 
catalase) and 2 µg/ml mycobactin J. Cells were harvested and 
aliquots of 100 mg wet cell pellet in PBS (pH 7.2) were made 
for inoculation. 100 mg of wet cells equals roughly 109 cfu (cfu 
numbers were identified through serial dilutions of 1 µl of the 
cells used for inoculation) the required dose per inoculum. 
Cells were suspended in 20 ml warm pasteurized whole cow 
milk to a concentration of 109 cfu per inoculum and transferred 
to a 20 ml sterile syringe. Ten goats were inoculated three 
times on consecutive days with this suspension of 109 cfu, one 
day more than recommended by the International Committee of 
Johne’s Disease Researchers [23]. The inoculation was 
performed when the goat kids were 7 weeks old at a time point 
at which obtained all results from the day 0 data set. The ten 
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goat kids within the negative control group received the same 
amount of milk but without the bacteria. 
C. Blood collection and white blood cell preparation 
Blood was collected prior the infection (termed day 0) and 
after inoculation at weeks 1, 3, and 8, and every four weeks 
thereafter. Characterization of samples collected on day 0 
including flow cytometry data from different goats have been 
published previously [24]. For each of the blood draw 8 – 10 
ml of blood were collected aseptically from the jugular vein 
into an EDTA solution for immediate analyses. Preparation of 
the peripheral blood leukocytes was performed as described 
previously [24]. Briefly, red blood cells were lysed with Gey’s 
solution (155 mM NH4Cl, 1 mM KHCO3). White blood cells 
were pelleted by centrifugation for 5 minutes at 259g at 4C. 
The supernatant was discarded and the white cell pellet was 
washed twice with PBS. Clean pellets were resuspended in 
complemented RPMI 1640 medium (8.7% fetal bovine serum, 
1 M HEPES buffer, 50x MEM without L-glutamine, 100 mM 
sodium pyruvate, 200 mM L-glutamine solution, penicillin 
[100 units/ml] and streptomycin [50 µg/ml] solution) 
(cRPMI). Four milliliters of blood were also drawn for serum 
collection, which was processed the same day and serum 
samples were stored at -80C until serological testing. 
 
D. Antigen solution preparation 
Antigens for cell stimulation included cRPMI media as a 
negative control, concanavalin A (ConA) as the positive 
control, bovine purified protein derivative (bPPD) (40 µg/ml), 
Para-LP-01 lipid (2.5 µg/ml), and Johnin purified protein 
derivative (JPPD) (20 µg/ml). 
 
E. Cell stimulation for cytokine ELISA 
The amount of 5x105 peripheral blood leukocytes were 
added per well to flat bottom, tissue culture 96-well plates 
(Corning Inc, NY).  One hundred microliter of antigen 
dilutions were added to the appropriate wells.  Plates were 
incubated 96 hours at 37°C, 5% CO2, 99% relative humidity, 
and then stored at -80°C until needed. 
F. Cytokine ELISA 
IFN monoclonal antibody bovine IFN-gamma-I 
(MabTech) and IL-10 capture antibody (AbD Serotec) were 
diluted in PBS (pH 7.2) (IFN: 25ul antibody per 1ml PBS; 
IL-10: 12.5ul antibody per 1ml PBS).  One hundred microliter 
of primary antibody per well were added to the appropriate 
plates.  Plates were incubated overnight at 4°C, then washed 
three times with 200ul PBS (pH 7.4) and blocked one hour at 
room temperature with 200 µl of a solution containing 3% 
bovine serum albumin and 5% Tween 20 in PBS, pH 7.4.  
Plates were washed again with 200 µl PBS (pH 7.4) per well.  
Supernatant from the antigen stimulated cells were added in a 
volume of 50 µl.  Plates were incubated for one hour at room 
temperature. 
 
IFN monoclonal biotinylated antibody (MabTech) and IL-
10 mouse antibovine interleukin-10: biotin (AbD Serotec) 
were diluted in 10% fetal bovine serum in PBS, pH 7.4 (IFN: 
2 µl antibody per 1 ml 2%FBS/PBS; IL-10: 2 µl antibody per 
1ml 2%FBS/PBS).  Plates were washed three times with PBS 
(pH 7.4).  One hundred microliter per well of secondary 
antibody solution were added to the appropriate plates.  Plates 
were incubated one hour at room temperature. HRP-
streptavidin was diluted 1:1000 in 10% FBS/PBS.  Plates were 
washed three times with 200 µl PBS (pH 7.2), 100 µl of HRP-
streptavidin were added per well and plates were incubated 1 
hour at room temperature in the dark. Plates were then washed 
three times with 200 µl PBS (pH 7.4) and 100 µl of 
3,3’,5,5’-Tetramethylbenzidine liquid substrate (Sigma) were 
added per well.  Plates were incubated at room temperature in 
the dark until color developed (approximately 10 minutes).  
To stop the reaction, 100 µl of 2N sulfuric acid were added 
per well.  Plates were read using an iMark Microplate Reader 
(BioRad) at a wavelength of 450 nm. 
 
G. ELISpot 
Two days prior to blood collection, MultiScreen Filter 
Plates (0.45 µm Hydrophobic, Millipore) were pre-wet with 
100 µl 35% ethanol per well.  Plates were incubated for 1 
minute before being washed three times with 150 µl PBS (pH 
7.2) per well.  IFN monoclonal antibody bovine IFN-gamma-
I (MabTech) or IL-10 Capture Antibody (AbD Serotec) were 
diluted in PBS (pH 7.2) (IFN: 15 µl antibody per 1ml PBS; 
IL-10: 7.5 µl antibody per 1ml PBS) and 100 µl of appropriate 
antibody solution were added per well.  Plates were incubated 
overnight at 4°C. 
 
Cells obtained from the goat blood were added as follows: 
IFN (all antigens except Concanavalin A) – 5x105 cells/well; 
IFN (concanavalin A) – 1.25x105 cells/well; IL-10 (all 
antigens except concanavalin A) – 1.25 x 105 cells/well; IL-10 
(concanavalin A) – 6.25 x 104 cells/well.  100 µl of diluted 
antigen solutions were added to the appropriate wells.  All 
animal/antigen combinations were performed in triplicate.  
Plates were incubated overnight at 37°C, 5% CO2, 99% 
relative humidity. 
 
IFN biotinylated monoclonal antibody (MabTech) and IL-
10 mouse anti-bovine interleukin-10: biotin (AbD Serotec) 
were diluted in 2% Fish Skin Gelatin (FSG)/PBS (pH 7.2) 
(IFN: 1 µl antibody per 1 ml 2% FSG/PBS; IL-10: 0.5 µl 
antibody per 1ml PBS).  Plates were washed three times with 
150 µl PBS per well.  100 µl of appropriate antibody dilutions 
were added per well.  Plates were incubated 2 hours at room 
temperature in the dark. HRP-Streptavidin was diluted 1:1000 
in 2% FSG/PBS.  Plates were washed three times with 200 l 
PBS (pH 7.2) and 100 µl of HRP-Streptavidin solution was 
added per well.  Plates were incubated 1 hour at room 
temperature in the dark. 
 
AEC substrate solution was prepared as in the eBioscience 
ELISpot Set Protocol.  Plates were washed three times with 
200 µl PBS (pH 7.2).  100 µl of AEC substrate solution were 
added per well.  Plates were incubated at room temperature in 
the dark until spots developed (approximately 15-30 minutes).  
Spot development was stopped by rinsing plates in warm 
water. Dried plates were read using a CTL-ImmunoSpot S6 
FluoroSpot equipped with Immunospot software version 5.0.9. 
 
H. Para-LP-01 ELISA 
Wells were coated with 100 ng Para-LP-01 dissolved in iso-
propanol.  Plates were incubated at room temperature until 
evaporated.  Plates were blocked for one hour at room 
temperature with 100 µl 3%BSA (in PBS, pH 7.4) per well.  
ELISA was performed as described recently [18]. Briefly, 100 
µl of each serum diluted 1:20 in 10% FBS/PBS (pH 7.4) was 
added to the wells and incubated for 30 minutes at room 
temperature. Plates were washed three times with PBS 
followed by adding secondary conjugated antibody (sheep 
anti-bovine IgG-h+l HRP conjugated antibody diluted 1:2000 
in 10% FBS/PBS). 100 µl of secondary antibody solution were 
added per well and plates were incubated at room temperature 
for 30 minutes.  Plates were washed as before and 100 µl of 
room temperature TMB were added per well.  Plates were 
incubated at room temperature for 10 minutes.  The reaction 
was stopped by adding 100 µl of 2N sulfuric acid per well.  
Plates were read at 450 nm using an iMark Microplate Reader 
(BioRad). 
 
I. Antibodies for cell markers and staining of cell markers 
Antibodies used for flow cytometry were the same as used 
in a previous study [24]. All antibodies were obtained from 
AbD Serotec (Raleigh, NC), except for CD14 monoclonal 
antibodies, which were purchased from BioLegend (San 
Diego, CA). 
 
J. Flow cytometry 
Flow cytometry was performed as described previously [24]. 
Briefly, samples were analyzed via flow cytometer 
(FACSCantoll, Becton Dickinson, USA) equipped with BD 
FACSDiva software (Becton Dickinson, USA). A minimum of 
10,000 events was collected per sample. Profiles were 
analyzed with FlowJo software (TreeStar, Ashland, OR, 
USA). The following panels were used: CD4/CD8, 
CD4/WC1, CD1/CD14, and MHC class II/CD14. Gate 
strategies included selections of cell populations according to 
their appearance in side and forward scatter as shown in 
Figure 1. Thereafter, the fluorescences of the positive cell 
signals were compared to their corresponding isotype-matched 
controls. The percentage of positive cells and intensity of 
fluorescence was recorded as percentage of positive cells and 
mean fluorescence channel (MFC), respectively. Specific cell 
populations (CD14+ granulocytes or CD14+ monocytes) were 
back gated to show the presence and amount of such 
population within the selected cell types. 
 
K. Statistical analyses for peripheral blood leukocyte 
population and for evaluation of diagnostic approaches 
Repeated measures analysis was used for both the 
peripheral blood leukocyte populations and the ELISpot 
data.  Analysis was done using SAS 9.3 (Cary, NC).  A 
separate repeated measures analysis was done for each cell 
type using Proc Mixed.   The within-subjects factor is time 
and the between-subjects factor is treatment group (infected or 
uninfected).  A time*treatment interaction term was also 
included in the model.  The arh(1) covariance structure was 
used, allowing for unequal variances at the different time 
points.  Comparisons of means between treatment groups at 
each time point were considered.  A Benjamini-Hochberg 
adjustment was applied to account for multiple testing across 
time points separately for each cell type [25]. Statistical 
significance was defined as a p-value of 0.05 or less.  We note 
that a log transformation of the ELISpot data was considered 
to satisfy model assumptions.  However, the conclusions were 
 
Figure 1: Gating strategy of the flow cytometry of the various subsets 
of leukocytes and specific cell surface markers used in this study. In 
the center of this figure is the primary flow cytometry plot of goat #0010 
(as one example for the gating strategy) at week #20 post infection. The 
center plot represents cell sorting according to cell size (FSC-A) and 
granulation (SSC-A). Lymphocytes are encircled as cells in small size 
and low in granulation. Monocytes are low in granulation but larger in 
size than lymphocytes. In contrast, granulocytes are high in granulation 
and medium in size. The top two plots represent the gating strategy for 
granulocytes positive for CD14 (y-axis) and, in this example, MHC class 
II positive granulocytes (x-axis) including back gating the CD14 positive 
granulocytes. The bottom two plots represent the gating strategy for 
lymphocytes. This cell population was used for analysis of markers CD4 
(x-axis in both plots) and CD8 (y-axis left plot) and WC1 (y-axis right 
plot). Finally, two plots on the right side of the figure represent the gating 
strategy for monocytes. This cell population was used for analysis for 
markers CD14 (y-axis in both plots) in combination with either marker 
CD1 (x-axis bottom plot) or marker MHC class II (x-axis top plot). The 
back gating strategy for the CD14 marker on monocytes is shown in the 
two plots to the far right. These plots show the presence of cells within 
this population that are CD14-. 
the same for both the original and log transformed data, so 
results on the original scale are presented here. 
 
L. Fecal culturing of MAP and Serology 
Fecal samples were obtained at the same time blood 
collection was performed. Culturing of MAP from fecal 
samples was performed at the Rocky Mountain Regional 
Animal Health Laboratory, Colorado Department of 
Agriculture Animal Industry Division. Serology for JD was 
performed by the Diagnostic Laboratory at the Veterinary 
Teaching Hospital at Colorado State University. Serology was 
performed using Paracheck (Prionics, Inc.) and an in-house 
developed AGID test. 
 
M. Weight 
Weights were obtained in pounds (lbs) with a commercially 
available scale until goats reached 50 pounds. The weight was 
determined by weighing the person holding the goat minus the 
weight of the person alone. After this period goat weights 
were determined with a hanging scale and a calf sling. 
Weights were obtained on a weekly basis during milk feeding 
and every month thereafter. Weights in pounds were later 
converted into kg (1 kg = 2.20462 lbs). Weights until the age 
of six months were already separately published [22]. 
 
III. RESULTS 
A. Fecal Cultures, Parachek ELISA, and AGID 
All animals in the study were tested monthly via standard 
diagnostic techniques (fecal culturing, Parachek ELISA, and 
AGID).  MAP could not be cultured at any time from fecal 
samples from any of the animals. Serology (Paracheck ELISA, 
AGID) for JD was negative for all goats (Data not shown). 
 
B. Cell Counts 
White blood cell counts were obtained from each goat 
throughout the study.  While the average cell counts between 
the inoculated and negative goats were never significant 
different (p < 0.05), the infected goats consistently showed a 
higher average than the uninfected goats. In week #1 and week 
#8 post infection the p-value was less than 0.1 (Figure 2). 
 
C. IFN ELISpot and IFN ELISA 
The IFN ELISpots for all three stimulatory antigens 
(bPPD, Para-LP-01, JPPD) are shown in Figure 3.  With the 
exception of weeks 24 to 31 post infection for bovine (bPPD) 
and Johnin PPD (jPPD) as stimulatory antigens, there were no 
statistically significant (p-value < 0.05) differences between 
the two groups. The statistical significance was lost when the 
results of one goat within the non-inoculated group with a 
Corynebacterium pseudotuberculosis infection were removed 
(data not shown). While other goats within both groups had 
slightly elevated reactivities during this hot and dry summer 
period, this goat specifically reacted more robustly than any of 
the other goats. The IFN ELISAs for all three stimulatory 
antigens (bPPD, Para-LP-01, and jPPD) are depicted in 
Figure 4.  No statistical significant differences were detected. 
 
D. IL-10 ELISpot and IL-10 ELISA 
The IL-10 ELISpots for all three stimulatory antigens 
(bPPD, Para-LP-01, and jPPD) are presented in Figure 5 
while those results for the IL-10 ELISA are shown in Figure 
6.  No statistical significant differences were detected. 
 
E. Para-LP-01 ELISA 
 
Figure 2: Total peripheral blood leukocyte cell count.  The p values of 
the two time points of interest are shown. Time scale is in weeks. 
 
Figure 3: Interferon gamma ELISpot on peripheral blood leukocytes 
stimulated with bovine PPD, Johnin PPD, or Para-LP-01 of MAP-
inoculated and non-inoculated goats. The amounts of interferon gamma 
are presented as counts per well. Results shown include the results of the 
non-inoculated goat with a subclinical C. pseudotuberculosis infection. 
Because the data were in general without statistical significance standard 
error bars are not included in this figure. Time scale is in weeks. 
 
Figure 4: Interferon gamma ELISA on peripheral blood leukocytes 
stimulated with bovine PPD, Johnin PPD, or Para-LP-01 of MAP-
inoculated and non-inoculated goats. Because there were no statistical 
significances measured standard error bars are not included in this figure. 
Time scale is in weeks. 
In addition to its use as a stimulatory antigen for cellular 
immune assays, Para-LP-01 was also used to determine 
humoral immune reactivity utilizing a lipid-based ELISA. The 
results for the Para-LP-01 ELISA are shown in Figure 7, 
Panel A. The overall average O.D. showed only for the weeks 
#8 and #24 statistical significance for the infected group to 
have an increased O.D. However, beside the average O.D. 
numbers individual infected goats reacted strongly at certain 
weeks throughout the study, especially goats #2 and #6 
(Figure 7, Panel B). Another observation was that the goats 
had stronger reactivity during the first few weeks of life and 
that this reactivity was reduce to normal levels during the first 
few months. 
 
F. Key Populations of Leukocytes 
The goat leukocyte samples were analyzed via flow 
cytometry to determine the abundance of the key populations: 
granulocytes, lymphocytes, and monocytes. The different cell 
types were defined as variable size and high granulation (SSC-
Ahigh/FSC-Avariable: granulocytes), as small size and low 
granulation (SSC-Alow/FSC-Alow: lymphocytes), and as 
medium size and low granulation (SSC-Alow/FSC-Amedium: 
monocytes). Percentages of granulocytes, lymphocytes, and 
monocytes were determined in panels CD4/CD8, CD4/WC1, 
and CD14/MHC class II. No statistical differences were found 
for granulocytes, lymphocytes, or monocytes at any time 
point. Data are summarized in Figure 8. Data from the other 
two panels showed very similar pattern (data not shown). The 
granulocyte populations did not appear different between the 
infected and uninfected goats. Monocytes in the infected goats 
seemed to have slightly increased throughout the first 31 
weeks. A different observation was made for the lymphocyte 
populations. Lymphocytes were slightly higher in uninfected 
goats in the first few weeks, while the monocytes are slightly 
increased in inoculated goats. 
 
 
Figure 5: IL-10 ELISpot on peripheral blood leukocytes stimulated 
with bovine PPD, Johnin PPD, and Para-LP-01 of MAP-inoculated 
and non-inoculated goats. Time scale is in weeks. 
 
Figure 6: IL-10 ELISA on peripheral blood leukocytes stimulated 
with bovine PPD, Johnin PPD, or Para-LP-01 of MAP-inoculated and 
non-inoculated goats. Time scale is in weeks. 
 
Figure 7: Para-LP-01 based Lipid-ELISA on sera from MAP-
inoculated and non-inoculated goats. Panel A shows the average OD for 
each goat group, while Panel B shows the average OD of each group in 
comparison to two inoculated goats with high intermitted OD values. 
Time scale is in weeks. 
 
Figure 8: Flow cytometry results of granulocytes (A), lymphocytes 
(B), and monocytes (C) in inoculated and uninfected goats. The 
percentage for each cell type is taken from the total leukocyte population. 
Time scale is in weeks. 
G. Lymphocyte Subpopulations 
The following goat lymphocyte populations were 
analyzed: CD4+ T cells, CD8+ T cells, CD4/CD8 double 
positive T cells, CD4/CD8 double negative T cells, and WC1+ 
 T cells. While CD4 and CD8 markers were analyzed in one 
panel,  T cells were analyzed in a separate panel with CD4 
as the second marker. T cells analyzed for CD4 and CD8 did 
not show any statistical significant changes throughout the 
study. However, there was a clear trend for CD4 positive T 
cells during the silent stage with an increased CD4+ T cell 
population in infected goats (Figure 9, Panel A). CD8+, 
CD4+/CD8+, and CD4-/CD8- T cell populations did not exhibit 
any trends or changes during the course of the study (Data not 
shown). Interestingly, WC1+  T cells populations showed 
statistically significant differences during the study. 
Throughout the study, the WC1+  T cells were decreased in 
the infected goats, and the decrease was statistically 
significant at week 24 (Figure 9, Panel B). Thus the overall 
decreased in the lymphocyte population in the infected goats 
might have been due to decreased amounts of WC1+  T 
cells. 
 
H. Monocyte Subpopulations 
The overall amount of monocytes was very small when 
compared to those of granulocytes and lymphocytes and 
significant differences were difficult to detect. The amount of 
CD14+ monocytes fluctuated during the study without clear 
trends. During weeks 1 to 20, with the exception for weeks 3 
and 8, there was an overall increase of CD14+ monocytes, 
however, without any statistical significance (Figure 10, 
Panel A). No differences were obtained between the 
Monocyte/CD14+/MHC class II+ populations in infected and 
uninfected goats. Interestingly, however, the MHC class II+ 
cells within the monocyte population that were CD14- were 
increased in the infected goats between weeks 24 and 31. 
Week #28 differences were statistically significant (Figure 10, 
Panel B). Furthermore, cells within the monocyte population 
without the markers CD14 and MHC class II had decreased 
numbers between the weeks 20 and 31 with statistically 
significant differences in week 28 (Figure 10, Panel C). The 
other interesting marker for antigen-presenting cells in 
mycobacterial infections is CD1. No differences were seen for 
monocytes expressing both markers (CD14, CD1) (data not 
 
Figure 9: Flow cytometry of selected T cell lymphocytes in infected 
and uninfected goats. Panel A shows the T cell lymphocyte population 
positive for CD4, while panel B shows the T cell lymphocyte population 
positive for WC1. * Indicates statistical significance with a p value of 
less than 0.05. Time scale is in weeks. 
 
Figure 10: Flow cytometry of monocyte subset. Panel A shows the 
subset of monocytes that are CD14+. Panel B shows the cells within the 
monocyte population that were CD14- but MHC class II+. Panel C shows 
the cell population within the monocytes that do not carry CD14 or MCH 
class II markers. * Indicates statistical significance with a p value of less 
than 0.05. Time scale is in weeks. 
 
Figure 11: Flow cytometry of cells within the monocytes that do not 
express CD14. Panel A shows the subset of those cells that do express 
CD1, while Panel B shows the subset of cells that do not express CD1. * 
Indicates statistical significance with a p value of less than 0.05. Time 
scale is in weeks. 
shown). However, cells within the monocyte population 
expressing CD1 but not CD14 demonstrated significant 
increase for weeks 28 and 31 (Figure 11, Panel A). A slight 
increase was also seen early on from week 1 to week 8 with no 
statistical significance for any of the weeks in this period, 
while week 28 and week 31 demonstrated statistical 
significance. Cells within the monocyte population expressing 
neither CD14 not CD1 were reduced starting at week #20 with 
statistical significance for weeks 20 to 31 (Figure 11, Panel 
B). 
 
I. Granulocytes Subpopulations 
While the majority of CD14 positive cells are monocytes 
there is a significant population of CD14 positive cells that are 
granulocytes. During the first weeks, no trend was seen for the 
CD14 positive granulocytes. After week 12 there were 
differences in the percentage of CD14+ granulocytes between 
the infected and uninfected goats. While the CD14+ 
granulocytes of uninfected goats dropped the percentage of 
CD14+ granulocytes of the infected goats was the same as in 
earlier weeks post infection (Figure 12, Panel A). 
Interestingly, a similar observation was made for a subset of 
those cells that also bear the marker MHC class II and were 
statistical significant in the same weeks as seen for CD14+ 
granulocytes (week 12, 16, and 28) (Figure 12, Panel B). 
 
J. Weight & Standard Diagnostics (serology, fecal culture) 
A brief analysis of the weight gain during the first 24 
months after inoculation was previously demonstrated [22]. 
Here we extend our analysis of the total weight development 
on a 4-week basis. There is a clear separation of the average 
weights of inoculated versus non-inoculated goats with several 
time points demonstrating statistical significance with a p-
value of less than 0.05 (weeks 22, 26, 34, and 42) (Figure 13). 
While an early significant difference in the weight gain was 
previously shown, we did not see a similar difference in 4-
week weight gain during this time period.  
 
All fecal cultures did not show any growth of 
Mycobacterium avium subsp. paratuberculosis. In addition, all 
serum samples had a negative serology using Paracheck. 
 
IV. DISCUSSION 
Currently available diagnostics for JD are unable to 
consistently diagnose animals before they begin shedding 
MAP or exhibit clinical features. This is especially true for the 
silent and subclinical stages of this chronic disease.  Since 
early diagnosis is key for controlling JD it is important to 
evaluate current diagnostics and new diagnostic tests during 
the pre-clinical stages as well as non-specific parameter such 
as weight gain, weight development, and peripheral blood 
leukocyte population changes. Thus, the overall scope of this 
study was to not only evaluate serology, cell-mediated 
immune assays, as well as the culturing of the pathogen from 
fecal samples during the silent stage, but also characterize 
immune cell population changes despite their non-specificity. 
In this study, we experimentally inoculated ten goats with 
MAP.  Blood and fecal samples were collected on a monthly 
basis to determine not only the immune status during the early 
silent stage of Johne’s disease and efficacy of diagnostic 
approaches but also to monitor changes in the various 
population of the peripheral leukocytes.  All results were 
compared to a control group of ten uninfected goats. 
 
The results from the ELISpot, cytokine ELISA, and lipid 
ELISA do not clearly indicate if any of the goats are infected 
with MAP.  There were no consistent significant differences 
between the two groups on any assay or with any antigen.  
Since the standard diagnostic assays (fecal culturing, Parachek 
ELISA, and AGID) have been negative for all goats thus far 
and we are testing new diagnostic approaches, we currently do 
not have a set “cut-off” value to determine whether an animal 
is positive or negative for Johne’s disease.  While there are 
currently few differences between the two groups, the results 
from the Para-LP-01 Lipid-ELISA seem promising. Some of 
the infected goats have shown an increased antibody response 
to Para-LP-01 on the lipid ELISA (#2 and #6). However, those 
results were never consistent. 
 
 
Figure 12: Flow cytometry of granulocytes that are positive for CD14. 
Panel A shows granulocytes that are CD14+, while panel B shows a 
subset of those cells that are also MHC II+. Time scale is in weeks. * 
Indicates statistical significance with a p value of less than 0.05. 
 
 
Figure 13: Weight development of goats inoculated with MAP versus 
the negative control group. Time scale is in weeks+. * Indicates 
statistical significance with a p value of less than 0.05. 
 
 
One goat in the uninfected group (goat #13) reacted 
strongly to bPPD and JPPD on the IFN ELISpot and ELISA.  
In these assays, he produced more IFN than the rest of the 
uninfected group and even of the infected group.  He reacted 
barely to Para-LP-01 on these assays but did not exhibit any 
antibody response to Para-LP-01 on the lipid ELISA. While 
not reacting to Para-LP-0 the goat showed an increase of 
antibody response through Paracheck. Considering that goat 
#13 produced negative results on standard diagnostic assays, 
reacted weakly or not at all to Para-LP-01, was not exposed to 
MAP as well as was obtained from a JD-free goat dairy, and 
had similar results on both PPDs we do not think that his 
reactivity toward bPPD and jPDD is an indication of JD but 
rather an indicator of an infection due to a similar bacterial 
pathogen, such as Nocardia and Corynebacteria [26,27].  C. 
pseudotuberculosis, the causative agent of caseous 
lymphadenitis, is notorious for producing false positive results 
in JD diagnostics [30]. Thus, we hypothesized a subclinical C. 
pseudotuberculosis infection was responsible for goat #13’s 
strong reactivity toward bPPD and jPPD. Para-LP-01 may be a 
useful tool in diagnosing JD since it shows low to no cross-
reactivity with animals infected with C. pseudotuberculosis. 
 
In an experimental infection of angora goats, Stewart et al 
(2006) saw an initial IFN response to JPPD at 6 months post 
infection with a consistent IFN response beginning at 16 
months post infection [29].  We did observe a peak in JPPD 
reactivity at 20 weeks post infection.  Perhaps, this peak is 
analogous to that observed by Stewart et al; however, this 
peak was observed in both groups.  Stewart et al. did not show 
IFN responses from their control animals; therefore, it is 
difficult to determine if the IFN response at 6 months post 
infection was due to JD. There is some debate over whether 
assays using components from the peripheral blood are 
effective in, or even capable of, diagnosing JD before fecal 
shedding occurs.  Lybeck et al. (2010) discovered that goats 
naturally infected with MAP tend to shed the bacterium before 
immune responses to the disease are detectable [30].  
 
Among the various subsets of monocytes analyzed in this 
study the most impressive results were obtained for monocytes 
expressing CD1 markers, which were more prominent in 
infected goats than in uninfected goats. CD1 molecules 
usually present lipid antigens and thus this is not a surprise 
since the majority of surface molecules in mycobacteria are 
lipids. Beard et al. (2000) investigated the role of  T cells 
and the presence of CD1 molecules [31]. While they found an 
increase of  T cells in the Peyer’s patches, no differences 
were found for the  T cells in the regional lymph nodes. 
They could not find any significant changes for the expression 
of CD1 in any of the analyzed tissues. 
 
Lymphocytes are part of the early immune responses in 
mycobacterial infections. Among those CD4+, CD8+, and  T 
cells are the most studied immune cells. CD4+ T cells are 
associated with strong early immune responses on 
mycobacterial infections. Two classical studies on early 
cellular immune responses in experimentally infected cows 
demonstrated that the specific cellular immune responses led 
by activated CD4+ T cells is detectable no earlier than 6 
months after inoculation. Most of these specific immune 
responses are significantly detectable around 9 months post 
infections. Our data were not in full accordance with those 
found by other studies on T cell populations during early 
infection in calves with JD [32,33]. The overall picture of 
CD4 T cells in the early infection is seen as a progressive 
increase of such cells with the expression of activation 
markers [32]. However, in our analyses of the CD4+ T cell 
populations we did not detect a steady increase on those cells 
in the peripheral blood. Although almost constantly higher 
numbers of those cells were found in infected goats, we did 
not observe a clear trend at all. 
 
Another key element of the cellular immune responses in 
JD, especially in cattle, is the involvement of  T cells. While 
two phenotypes of  T cells were identified with respect to 
the presence of specific surface markers (CD8, CD2, and 
WC1) and the related cytokine profiles, we analyzed only the 
WC1+ population of  T cells. The  T cells that are WC1+ 
exhibit more pro-inflammatory characteristics while the other 
subset of  T cells shows anti-inflammatory properties [31]. 
The pro-inflammatory properties of the WC1+ subset are 
greatly related to their strong production of IFN- and IL-2 
[31]. Badi et al. (2010) described an increase of such cells in 
non-seroconverted cattle with JD, while we did not observe 
such increase [34]. In our study this specific subset of  T 
cells was steadily declining and was always less present in 
infected goats when compared to uninfected goats. The 
differences in the observation might be due to the time point 
of evaluation with our goats being less than 1 year old and the 
cattle studied by Badi et al. (2010) are at least 2 years old [34].  
 
The most surprising observation was the strong 
differences in weight gain during the first weeks after 
inoculation and the constant differences in the weight 
development between the inoculated and the uninfected goats. 
While reduced weight gain and reduced weight development 
are non-specific characteristics of any chronic disease, this 
still seems to be a surprise to us since we did not observe any 
clinical symptoms or positive results through specific 
diagnostics. 
 
The goals of this study were (1) to test new diagnostic 
approaches using the Para-LP-01 lipid of MAP to potentially 
diagnose animals during the silent or sub-clinical stage of JD, 
and (2) to evaluate non-specific markers such as peripheral 
blood leukocytes.  Thus far, we have no conclusive evidence 
of the efficacy of these approaches but have discovered that 
Para-LP-01 may be a useful tool in diagnosing JD in animals 
that may have been exposed to the similar bacterium C. 
pseudotuberculosis. Furthermore, we found that during the 
silent stage of JD changes occur in the various subsets of 
peripheral blood leukocytes. Finally, it seems that early weight 
gain differences as well as weight development during the 
silent phase are excellent non-specific characteristics pointing 
toward Johne’s disease in dairy farms that are suspected to 
have this chronic disease.   
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